SAVA

Cassava Sciences, Inc. [SAVA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SAVA Stock Summary

Top 10 Correlated ETFs

SAVA


Top 10 Correlated Stocks

SAVA


In the News

09:15 29 Mar 2024 SAVA

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer's and Parkison's Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.

04:50 29 Mar 2024 SAVA

Exit Now! 3 Biotech Stocks to Sell in February 2024

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges.

10:16 29 Mar 2024 SAVA

3 small-cap biotechs with potential breakthroughs in 2024

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

10:15 29 Mar 2024 SAVA

Is There Any Hope for Cassava Sciences Stock?

Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to produce favorable data.

05:29 29 Mar 2024 SAVA

3 Biotech Stocks to Sell in January Before They Crash and Burn

The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies' performance relies heavily on drug approvals.

02:21 29 Mar 2024 SAVA

Portfolio Protection: 7 Risky Stocks to Drop Right Now

With investors moving back towards a “risk-on” stance in recent months, you may think that risky stocks could lead to outsized rewards this year. Yet while more favorable economic and market conditions could extend the current bull market (which started in October) well into 2024, an improving macro picture may not be enough for stocks that have large company-specific risks.

11:46 29 Mar 2024 SAVA

New SAVAW Warrants Are Trading After Cassava Sciences' Distribution

In the biotechnology sector, Cassava Sciences (NADSAQ: SAVA ) remains one of the top clinical-stage companies that investors are watching. Over the past one year, SAVA stock is down by less than 20% but up nearly 9% for the past six months.

06:06 29 Mar 2024 SAVA

Why Cassava Sciences Stock Zoomed 21% Higher This Week

The biotech has declared a fresh dividend. The payout is rather atypical -- it's in the form of common stock warrants.

02:02 29 Mar 2024 SAVA

Why Is Cassava Sciences (SAVA) Stock Up 15% Today?

Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over management's decision to issue a warrant distribution to support the ongoing Phase 3 clinical development of oral simulfilam, a promising therapeutic for patients of Alzheimer's disease.

07:31 29 Mar 2024 SAVA

Why Cassava Sciences Stock Soared Today

The biotech significantly modified its board of directors. Two of those incoming directors have extensive experience in the healthcare field; the other comes from the security sphere.

SAVA Financial details

Company Rating
Neutral
Market Cap
856.29M
Income
-94.59M
Revenue
2.35M
Book val./share
3.26
Cash/share
2.87
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-11.07
Forward P/E
12.06
PEG
-4.33
P/S
-562087.03
P/B
6.5
P/C
7.02
P/FCF
-12.48
Quick Ratio
8.25
Current Ratio
8.62
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.26
EPS next Y
1.67
EPS next Q
-0.46
EPS this Y
28.89%
EPS next Y
-173.89%
EPS next 5Y
-17.26%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-18.03%
-
-
-
-
SMA20
-8.7%
SMA50
-16%
SMA100
-
Inst Own
24.97%
Inst Trans
0.93%
ROA
-53%
ROE
-48%
ROC
-0.67%
Gross Margin
100%
Oper. Margin
5805333%
Profit Margin
5055389%
Payout
-
Shs Outstand
43.23M
Shs Float
39.16M
-
-
-
-
Target Price
-
52W Range
12.32-32.1
52W High
-37.08%
52W Low
+67.78%
RSI
44
Rel Volume
0.42
Avg Volume
715.81K
Volume
302.26K
Perf Week
-8.36%
Perf Month
-18.06%
Perf Quarter
5.63%
Perf Half Y
13.04%
-
-
-
-
Beta
-0.419
-
-
Volatility
0.49%, 1.37%
Prev Close
-1.4%
Price
20.1332
Change
2.15%

SAVA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.24-0.22-0.81-1.8-2.32
Operating cash flow per share
-0.14-0.21-0.77-1.93-1.96
Free cash flow per share
-0.15-0.21-1.33-2-1.97
Cash per share
1.333.585.9252.89
Book value per share
1.273.536.445.663.28
Tangible book value per share
1.273.536.425.643.27
Share holders equity per share
1.273.536.445.663.28
Interest debt per share
0.010.010.01-0.090
Market cap
90.54M178.04M1.72B1.19B943.89M
Enterprise value
67.55M84.82M1.49B986.69M822.75M
P/E ratio
-21.33-30.41-54.15-16.39-9.71
Price to sales ratio
000-659.76K0
POCF ratio
-36.02-33.08-57.03-15.32-11.51
PFCF ratio
-35.76-33.08-32.86-14.8-11.45
P/B Ratio
4.11.936.785.226.87
PTB ratio
4.11.936.785.226.87
EV to sales
000-548.16K0
Enterprise value over EBITDA
-13.62-11.88-45.3-12.33-7.88
EV to operating cash flow
-26.87-15.76-49.3-12.73-10.03
EV to free cash flow
-26.68-15.76-28.41-12.3-9.98
Earnings yield
-0.05-0.03-0.02-0.06-0.1
Free cash flow yield
-0.03-0.03-0.03-0.07-0.09
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
4.6413.067.12.511.16
Current ratio
16.8350.419.5129.919.13
Interest coverage
00021.20
Income quality
0.540.850.931.020.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000-6.66K0
Research and developement to revenue
000-37.8K0
Intangibles to total assets
00000
Capex to operating cash flow
0.0100.740.030.01
Capex to revenue
0001.51K0
Capex to depreciation
-0.310-41.6-2.08-0.27
Stock based compensation to revenue
000-1.15K0
Graham number
2.644.2210.8215.1513.08
ROIC
-0.2-0.06-0.13-0.33-0.77
Return on tangible assets
-0.18-0.06-0.12-0.31-0.64
Graham Net
1.253.55.64.822.57
Working capital
21.96M92.13M231.95M204.16M115.44M
Tangible asset value
22.1M92.2M252.84M226.92M137.29M
Net current asset value
21.96M91.89M231.62M203.93M115.44M
Invested capital
00000
Average receivables
0000481K
Average payables
373.5K682K4.02M5.57M7.3M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
2.85K961.034.87K1.13K2.52K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.130.380.070.320.14
Inventory turnover
00000
ROE
-0.19-0.06-0.13-0.32-0.71
Capex per share
00-0.56-0.07-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.06
Net income per share
-0.43-0.52-0.63-0.61-0.5
Operating cash flow per share
-0.52-0.32-0.48-0.63-0.53
Free cash flow per share
-0.51-0.33-0.48-0.63-0.53
Cash per share
4.934.494.033.392.87
Book value per share
5.584.894.293.693.26
Tangible book value per share
5.574.884.283.693.25
Share holders equity per share
5.584.894.293.693.26
Interest debt per share
-0.04-0.06000.06
Market cap
1.2B1.01B1.02B698.91M949.65M
Enterprise value
1B819.28M856.33M556.56M828.52M
P/E ratio
-17.37-11.63-9.71-6.81-11.35
Price to sales ratio
-669.16K000404.45
POCF ratio
-56.5-75.95-51.43-26.34-42.55
PFCF ratio
-57.4-73.96-51.45-26.32-42.48
P/B Ratio
5.294.935.714.516.91
PTB ratio
5.294.935.714.516.91
EV to sales
-557.57K000352.86
Enterprise value over EBITDA
-47.94-30.9-29.76-19.96-36.93
EV to operating cash flow
-47.07-61.81-42.98-20.98-37.13
EV to free cash flow
-47.83-60.19-42.99-20.96-37.06
Earnings yield
-0.01-0.02-0.03-0.04-0.02
Free cash flow yield
-0.02-0.01-0.02-0.04-0.02
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
9.597.075.855.115.4
Current ratio
29.9114.029.758.629.13
Interest coverage
11.6110.2200-8.66
Income quality
1.110.550.761.031.07
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
-1.83K0001.73
Research and developement to revenue
-9.81K0007.98
Intangibles to total assets
00000
Capex to operating cash flow
-0.020.03000
Capex to revenue
-186.11000-0.02
Capex to depreciation
0.86-0.910.02-0.06-0.12
Stock based compensation to revenue
-342.220000.91
Graham number
7.317.557.817.126.03
ROIC
-0.08-0.12-0.14-0.16-0.23
Return on tangible assets
-0.07-0.1-0.13-0.15-0.14
Graham Net
4.754.153.612.982.55
Working capital
204.16M181.09M156.64M132.77M115.44M
Tangible asset value
226.92M203.5M178.97M154.85M137.29M
Net current asset value
203.93M180.89M156.64M132.77M115.44M
Invested capital
00000
Average receivables
00664K1.31M1.12M
Average payables
3.78M6.13M9.29M9.92M10.03M
Average inventory
00-664K-1.31M-642.5K
Days sales outstanding
000036.87
Days payables outstanding
929.381.9K2.38K2.18K2.67K
Days of inventory on hand
00-305.68-295.030
Receivables turnover
00002.44
Payables turnover
0.10.050.040.040.03
Inventory turnover
00-0.29-0.310
ROE
-0.08-0.11-0.15-0.17-0.15
Capex per share
0.01-0.01000

SAVA Frequently Asked Questions

What is Cassava Sciences, Inc. stock symbol ?

Cassava Sciences, Inc. is a US stock , located in Austin of Tx and trading under the symbol SAVA

What is Cassava Sciences, Inc. stock quote today ?

Cassava Sciences, Inc. stock price is $20.1332 today.

Is Cassava Sciences, Inc. stock public?

Yes, Cassava Sciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap